Treatment of Anti-NMDA Receptor Encephalitis
Start first-line immunotherapy immediately with high-dose corticosteroids (or IVIG/plasma exchange if steroids contraindicated) once infection is ruled out, and escalate rapidly to combination therapy or second-line agents (rituximab) if no improvement occurs within 2-4 weeks. 1
Initial Management Algorithm
First-Line Immunotherapy
Begin treatment as soon as basic CSF results exclude infection, without waiting for antibody confirmation 1:
- High-dose corticosteroids (typically IV methylprednisolone)
- Alternative first-line options if steroids contraindicated:
- IVIG (preferred in agitated patients or those with bleeding disorders)
- Plasma exchange/PLEX (5-10 sessions every other day; preferred in severe hyponatremia, high thromboembolism risk, or associated demyelination) 1
Escalation Strategy for Severe Presentations
For severe initial presentations (severe NMDAR encephalitis, new-onset refractory status epilepticus, severe dysautonomia), consider combination first-line therapy from the beginning rather than sequential treatment 1:
- Steroids + IVIG, or
- Steroids + PLEX
This approach is recommended despite limited high-quality evidence supporting upfront combination therapy, as the severity of presentation justifies aggressive initial treatment 1.
When to Add Second Agent
If no clinical, radiological, or electrophysiological improvement occurs by the end of the initial treatment cycle 1:
- Add IVIG or PLEX to the initial corticosteroid regimen
- Most clinicians (62% in expert surveys) prefer adding a different first-line agent sequentially before escalating to second-line therapy 1
Second-Line Immunotherapy
Initiate second-line agents if no meaningful improvement occurs 2-4 weeks after completing combined first-line therapy 1:
Rituximab (Preferred for NMDAR Encephalitis)
Rituximab is the preferred second-line agent for confirmed or highly suspected NMDAR encephalitis because this is antibody-mediated autoimmunity 1:
- Dosing regimens:
- 375 mg/m² weekly for 4 weeks, OR
- 1000 mg given twice, 2 weeks apart 1
- Less toxic than cyclophosphamide
- Works primarily on B-cells but indirectly suppresses T-cell activity 1
Cyclophosphamide
Consider cyclophosphamide (600-1000 mg/m²) for cell-mediated autoimmunity or classical paraneoplastic syndromes 1
Novel Therapies for Refractory Cases
If no improvement with conventional second-line therapies, consider 1:
- Tocilizumab (IL-6 inhibitor)
- Bortezomib (proteasome inhibitor)
- Note: Minimal evidence supports these approaches; use only in truly refractory cases
Bridging/Maintenance Therapy
After acute treatment response, initiate bridging therapy to prevent relapse 1:
- Gradual oral prednisone taper, OR
- Monthly IV immunoglobulin, OR
- Monthly IV methylprednisolone
Critical caveat: Patients not treated with immunotherapy at first presentation have higher relapse risk 2. Weaning should be very gradual, with serial antibody level monitoring in serum and CSF when available 2.
Tumor Screening
Perform comprehensive cancer screening with CT chest/abdomen/pelvis with contrast 1:
- If negative, consider mammogram/breast MRI, pelvic ultrasound, and/or whole-body FDG-PET
- Particularly important in young women (ovarian teratoma association) 3
- Tumor removal is essential when identified 3
Common Pitfalls to Avoid
- Delaying treatment while awaiting antibody results - Start immunotherapy based on clinical suspicion once infection excluded 1, 2
- Inadequate escalation - Don't persist with ineffective monotherapy; escalate within 2-4 weeks 1
- Premature discontinuation - Recovery can be slow, especially in NMDAR encephalitis; responses may take weeks 2, 3
- Insufficient tumor screening - Exhaustive imaging is required, particularly for ovarian teratomas 3
- Using PLEX in agitated patients - IVIG is more suitable for agitated patients; PLEX requires cooperation and central line placement 1
Treatment Timeline Expectations
Early treatment initiation significantly improves outcomes 4. The in-hospital course can extend for months, followed by extensive rehabilitation 3. Most patients (83%) achieve good outcomes (modified Rankin Scale ≤2) within 6 months, with 62.5% achieving complete recovery 5.